These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

971 related articles for article (PubMed ID: 23109356)

  • 1. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
    Arnold JC; Boucher AA; Karl T
    Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
    Roser P; Vollenweider FX; Kawohl W
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
    Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
    Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
    Dos Santos RG; Hallak JEC; Crippa JAS
    Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
    Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
    Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the mechanism whereby cannabis use increases risk of psychosis?
    Luzi S; Morrison PD; Powell J; di Forti M; Murray RM
    Neurotox Res; 2008 Oct; 14(2-3):105-12. PubMed ID: 19073418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.
    Morgan CJ; Curran HV
    Br J Psychiatry; 2008 Apr; 192(4):306-7. PubMed ID: 18378995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
    Hahn B
    Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Cannabidiol Safety: A Review.
    Singh C; Rao K; Yadav N; Vashist Y; Chugh P; Bansal N; Minocha N
    Curr Drug Saf; 2023; 18(4):465-473. PubMed ID: 36056846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.
    Morgan CJA; Freeman TP; Hindocha C; Schafer G; Gardner C; Curran HV
    Transl Psychiatry; 2018 Sep; 8(1):181. PubMed ID: 30185793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis.
    Hall W; Degenhardt L
    BMJ; 2015 Mar; 350():h1205. PubMed ID: 25739398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 49.